Germplasm Bank
The Germplasm Bank is committed to providing healthy and viable seed, as well as reliable information on the collections of maize and wheat genetic resources it preserves; carrying out the activities required for seed introduction, processing, conservation, and distribution; complying with international agreements and standards; and hiring qualified staff to ensure that the requirements of our clients are met. The Bank is thus committed to complying with ISO 9001:2008 and continually improving the effectiveness of the Quality Management System. The Global Plan of Action (GPA) for plant genetic resources for food and agriculture aims to promote the conservation, sustainable utilization, and fair and equitable sharing of benefits of plant genetic resources. It is designed to contribute to the implementation of the Convention on Biological Diversity in the field of food and agriculture. The Plant Genetic Resource Center's specially designed vaults currently hold some 28,000 samples of maize and teosinte, a wild relative of maize, and 140,000 Triticeae samples, including bread wheat, durum wheat, and triticale (a man-made crop developed by crossing wheat with rye), with significant collections of barley, rye, and primitive and wild relatives of wheat. The Center also maintains a living collection of Tripsacum, a more distant maize relative.
ESBB conference Johannesburg, South Africa, Global Biobanking London, UK, HandsOn Biobanks 2016 conference Vienna, Austria, Managing Biomarker-Driven Clinical Trials Miami, USA, Genomic Sample Prep and Biomarker Assay Development San Francisco, USA, 2nd International Symposium on Germplasm of Ornamentals Atlanta, Georgia, IX International Symposium on In Vitro Culture and Horticultural Breeding Giza, Egypt, International Symposium on Role of Plant Genetic Resources on Reclaiming Lands and Environment Deteriorated by Human and Natural Actions Shiraz, Iran, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.
According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.
- Seed bank
- Spores and Mushroom Spores Bank
- Artificial seed production
- Plant Biobank
Related Conference of Germplasm Bank
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
22nd World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
17th International Conference on Human Genetics and Genetic Diseases
Germplasm Bank Conference Speakers
Recommended Sessions
- Biobanking Informatics
- Biorepository & Biospecimen
- Cryopreservation Methods
- Data Enrichment in Biobanks
- Ethical, legal and social issues in maintence of Biobanks
- Fertility biobanks
- Frontiers in Bioengineering and Biomaterials
- Germplasm Bank
- Next Generation Biobanking
- Quality Management Systems for Biobanking
- Stemcell Banking
- Tissue engineering
- Vitrification
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)

